Ozanimod Controls MS Disease Activity Regardless of Age
Meeting Coverage > > ACTRIMS-- Clinical, radiologic steps stayed steady or enhanced in both more youthful and older clients
by Ed Susman, Contributing Writer, MedPage Today March 3, 2024
WEST PALM BEACH, Fla.-- Clinical and radiologic procedures of illness activity stayed steady or enhanced for falling back numerous sclerosis (RMS) clients in all age over 7 to 8 years of constant treatment with ozanimod (Zeposia).
"Regardless of age classification, the adjusted annualized regression rate was listed below 0.2 in the stage III moms and dad trials and stayed low in the DAYBREAK open-label extension in clients treated with constant ozanimod," stated Jeffrey...